Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.58 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.45 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12893333 | 0.98 | ESR1 (0.59) | ESR1ESR2KDM1ASLC6A4SLC6A2 | |
| SCHEMBL12893212 | 0.88 | KDM1A (0.50) | KDM1ASLC6A4SLC6A2SLC22A1OPRM1 | |
| SCHEMBL1255410 | 0.83 | GRIN2B (0.44) | KDM1ASLC6A4SLC6A2SLC22A1OPRM1 | |
| SCHEMBL12893340 | 0.83 | GRIN2B (0.44) | KDM1ASLC6A4SLC6A2SLC22A1OPRM1 | |
| SCHEMBL8760127 | 0.82 | ESR2 (0.71) | ESR1ESR2SLC6A4SLC6A3 | |
| SCHEMBL27363396 | 0.79 | SLC6A4 (0.43) | ESR1ESR2KDM1ASLC6A4SLC6A2 | |
| SCHEMBL12893173 | 0.79 | ESR1 (0.71) | ESR1ESR2SLC6A4SLC22A1OPRM1 | |
| SCHEMBL6598136 | 0.79 | SIGMAR1 (0.51) | OPRM1OPRD1OPRK1 | |
| SCHEMBL14531882 | 0.78 | ESR1 (0.65) | ESR1ESR2OPRM1OPRD1OPRK1 | |
| SCHEMBL12893176 | 0.78 | ESR1 (0.65) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12161630-B2 | Methods to control infection using new generation small molecule growth inhibitors | OHIO STATE INNOVATION FOUNDATION (US) | 2024-12-10 | — | — | US | disclosed |
| US-20230094112-A1 | METHODS TO CONTROL INFECTION USING NEW GENERATION SMALL MOLECULE GROWTH INHIBITORS | OHIO STATE INNOVATION FOUNDATION | 2023-03-30 | — | — | US | disclosed |
| US-11478454-B2 | Methods to control infection using new generation small molecule growth inhibitors | OHIO STATE INNOVATION FOUNDATION (US) | 2022-10-25 | — | — | US | disclosed |
| US-20200405691-A1 | METHODS TO CONTROL INFECTION USING NEW GENERATION SMALL MOLECULE GROWTH INHIBITORS | OHIO STATE INNOVATION FOUNDATION | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11478454-B2 | Methods to control infection using new generation small molecule growth inhibitors | SMURF1, SMURF2, SMYD3 | ESR1 4611/4885ESR2 4540/4885KDM1A 1837/4885 |
| US-20230094112-A1 | METHODS TO CONTROL INFECTION USING NEW GENERATION SMALL MOLECULE GROWTH INHIBITORS | SMURF1, SMURF2, SMYD3 | ESR1 4626/4885ESR2 4540/4885KDM1A 1922/4885 |
| US-12161630-B2 | Methods to control infection using new generation small molecule growth inhibitors | SMURF1, SMURF2, SMYD3 | ESR1 4611/4885ESR2 4540/4885KDM1A 1837/4885 |
| US-20200405691-A1 | METHODS TO CONTROL INFECTION USING NEW GENERATION SMALL MOLECULE GROWTH INHIBITORS | SMURF1, SMURF2, SMYD3 | ESR1 4611/4885ESR2 4540/4885KDM1A 1837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.